The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis
Dosisabhängige protektive Effekte neuer Antidiabetika auf Delir, Depression, Demenz und Koma: Evidenz aus einer Netzwerk-Metaanalyse
Journal of the Royal Society of Medicine · 2026-02 · 119 (2) · 46-54
DOI: 10.1177/01410768251395877 ↗Auf einen Blick
In 62 RCTs mit 200.068 Teilnehmenden wurden GLP-1-Rezeptoragonisten und SGLT2-Inhibitoren verglichen. Nur hochdosiertes Dapagliflozin senkte Delir und Depression signifikant.
Fragestellung
Unterscheiden sich GLP-1-Rezeptoragonisten und SGLT2-Inhibitoren hinsichtlich Delir, Depression, Demenz und Koma?
Methode
Frequenzistische Netzwerk-Metaanalyse von RCTs; Robustheitsprüfung mit Bayes-Framework. Eingeschlossen wurden Personen ohne kognitive oder psychiatrische Vorerkrankung.
Ergebnisse
62 RCTs mit 200.068 Teilnehmenden. Nur hochdosiertes Dapagliflozin (10 mg/Tag) reduzierte Delir und Depression signifikant, besonders bei Typ-2-Diabetes. Dulaglutid und Liraglutid waren mit kognitiver Verbesserung verbunden.
Schlussfolgerung der Autor:innen
Die Analyse zeigt agentenspezifische neuroprotektive Profile: SGLT2-Inhibitoren, besonders hochdosiertes Dapagliflozin, könnten Delir und Depression mindern; GLP-1-Rezeptoragonisten, vor allem Dulaglutid und Liraglutid, könnten die Kognition verbessern.
Kernaussagen
- Nur hochdosiertes Dapagliflozin senkte Delir und Depression signifikant
- Dulaglutid und Liraglutid waren mit kognitiver Verbesserung verbunden
- Für Demenz und Koma zeigten sich keine signifikanten Vorteile
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Metaanalyse in der Zeitschrift Journal of the Royal Society of Medicine, online erschienen am 08.12.2025. Verfasst von Ping-Tao Tseng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung 804, Taiwan. Hauptthemen laut MEDLINE: Dementia, Delirium, Hypoglycemic Agents, Coma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Depression, Delir, Demenz
Abstract (Originalsprache)
Objectives
Emerging evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors may exert neuroprotective effects. However, the comparative efficacy of individual agents remains unclear. This network meta-analysis (NMA) aimed to evaluate the differential impacts of these therapies on the incidence of mental status changes, specifically delirium, depression, dementia and coma.
Design
A frequentist NMA was conducted using data from randomised controlled trials (RCTs) investigating GLP-1 receptor agonists or SGLT2 inhibitors. The robustness of the findings was verified through a Bayesian NMA framework.
Setting
This study adopted a confirmatory framework focusing on pre-defined neuropsychiatric adverse outcomes in alignment with Cochrane recommendations.
Participants
Included trials enrolled individuals without baseline cognitive or psychiatric disorders. Main outcome measures: The primary endpoint was the incidence of delirium, depression, dementia or coma during treatment. Secondary endpoints included changes in cognitive performance and drop-out rates.
Results
A total of 62 RCTs comprising 200,068 participants were included. Among all treatments, only high-dose dapagliflozin (10 mg/day) significantly reduced the occurrence of delirium and depression, particularly in patients with type 2 diabetes. Dulaglutide and liraglutide were the only agents associated with cognitive improvement. No significant benefits were observed for dementia or coma across all agents.
Conclusions
This analysis highlights agent-specific neuroprotective profiles: SGLT2 inhibitors, especially high-dose dapagliflozin, may mitigate the onset of delirium and depression, while GLP-1 receptor agonists, notably dulaglutide and liraglutide, may enhance cognitive function. These findings warrant consideration in selecting antihyperglycemic therapies for individuals at elevated neuropsychiatric risk.
Trial registration
PROSPERO CRD42024601021. The study protocol was approved by the Institutional Review Board of the Tri-Service General Hospital, National Defense Medical Center (TSGHIRB E202516007).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
- Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
- Department of Psychology, College of Medical and Health Science, Asia University, Taichung 413, Taiwan.
- Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung 811, Taiwan.
- Department of Internal Medicine, E-Da Dachang Hospital, I-Shou University, Kaohsiung 807, Taiwan.
- Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
ORCID-Profile: Ping-Tao Tseng, Chih-Wei Hsu, Kuan-Pin Su, Chih-Sung Liang
Zitieren
APA
Tseng, P. T., Zeng, B. Y., Hsu, C. W., Suen, M. W., Hung, C. M., Carvalho, A. F., Stubbs, B., Chen, Y. W., Chen, T. Y., Lei, W. T., Lin, P. Y., Chen, J. J., Su, K. P., Wang, H. Y., Zeng, B. S., Shiue, Y. L., & Liang, C. S. (2026). The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis. Journal of the Royal Society of Medicine, 119(2), 46-54. https://doi.org/10.1177/01410768251395877
Vancouver
Tseng PT, Zeng BY, Hsu CW, Suen MW, Hung CM, Carvalho AF, et al. The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis. Journal of the Royal Society of Medicine. 2026;119(2):46-54. doi:10.1177/01410768251395877
BibTeX
@article{Tseng2026,
author = {Tseng, Ping-Tao and Zeng, Bing-Yan and Hsu, Chih-Wei and Suen, Mein-Woei and Hung, Chao-Ming and Carvalho, Andre F and Stubbs, Brendon and Chen, Yen-Wen and Chen, Tien-Yu and Lei, Wei-Te and Lin, Pao-Yen and Chen, Jiann-Jy and Su, Kuan-Pin and Wang, Hung-Yu and Zeng, Bing-Syuan and Shiue, Yow-Ling and Liang, Chih-Sung},
title = {The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis},
journal = {Journal of the Royal Society of Medicine},
year = {2026},
volume = {119},
number = {2},
pages = {46--54},
doi = {10.1177/01410768251395877}
}
EUVIMED